← Back to headlines
Fulcrum Therapeutics Merges with Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics has announced a merger with Slate, a biotech company focused on migraine treatments, in a deal valued at $245 million.
17 Aug, 13:02 — 17 Aug, 13:02
Sources
Showing 1 of 1 sources
Related Stories
IMF Chief Warns Global Economy Faces Energy Shocks and Fiscal Pressures
17m ago
Abercrombie & Fitch Shares Surge on Strong Second-Quarter Earnings and Raised Guidance
33m ago
TWG Global Denies Fraud Allegations and Lakers Fire Sale Rumors Amid Federal Probe
37m ago
Montenegro Official Rejects Alleged Political Pressure Attempts
39m ago